Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Melanoma 1Leukemia, Promyelocytic, Acute 1Carcinoma, Basal Cell 1Breast Neoplasms 1

Interventions

fludarabine phosphate 24Peripheral Blood Stem Cell Transplantation 21Cyclophosphamide 21Busulfan 19Whole-Body Irradiation 15Tacrolimus 15Mycophenolic Acid 13Methotrexate 12ruxolitinib 11Cyclosporine 10Antilymphocyte Serum 10fludarabine 8Melphalan 7peginterferon alfa-2a 6Aspirin 6Filgrastim 5Stem Cell Transplantation 4Radiotherapy 4Imatinib Mesylate 4Hydroxyurea 4Flow Cytometry 4Etoposide 4Decitabine 4Biopsy 4Azacitidine 4Thiotepa 3Surveys and Questionnaires 3Prednisone 3Methylprednisolone 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Polycythemia Vera × arsenous acid × Clear all
NCT01014546 2022-07-22

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Roswell Park Cancer Institute

Phase 1 Terminated
5 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡